G1 Therapeutics buy melinda
Summary
This prediction ended on 23.02.18 with a price of €20.11. The BUY prediction by melinda finished with a performance of 17.56%. melinda has 50% into this predictionG1 Therapeutics is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer. Their lead product candidate, Trilaciclib, is designed to improve the outcomes of chemotherapy by preserving hematopoietic stem cells and immune system function. G1 Therapeutics is also developing therapeutics for lung cancer, glioblastoma multiforme, and other solid tumors. The company went public in May 2017 and is listed on the NASDAQ exchange under the symbol GTHX.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
G1 Therapeutics | 12.075% | 12.075% | 3.304% | -85.999% |
iShares Core DAX® | 1.395% | -0.272% | 17.642% | 15.576% |
iShares Nasdaq 100 | 2.287% | 6.912% | 37.651% | 51.525% |
iShares Nikkei 225® | 1.617% | 3.038% | 12.910% | 8.243% |
iShares S&P 500 | 0.659% | 3.687% | 29.434% | 44.236% |
Comments by melinda for this prediction
In the thread G1 Therapeutics diskutieren
Biotechnologie und medizinische SecteurRecherche
G1 Therapeutics, Inc. entwickelt Medikamente zur Behandlung von Krebs.
Es ist ein pharmazeutisches Unternehmen , die klinische Phase , die auf die Entdeckung und Entwicklung neuer Therapien für kleine Moleküle konzentriert sich wichtige unerfüllte Bedürfnisse in der Onkologie zu adressieren.
Das Unternehmen wurde von Kwok-Kin Wong und Norman E. Sharpless Mai 2008 19, gegründet und ist in Research Triangle Park, NC ansässig.
Anzahl der Mitarbeiter: 31 Personen.